|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xu YY, Wu HJ, Ma HD, Xu LP, Huo Y and Yin
LR: MicroRNA-503 suppresses proliferation and cell-cycle
progression of endometrioid endometrial cancer by negatively
regulating cyclin D1. FEBS J. 280:3768–3779. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Prat J: Pathology of cancers of the female
genital tract. Int J Gynaecol Obstet. 131 Suppl 2:S132–S145. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jin J: Vaginal and urinary symptoms of
menopause. JAMA. 317:13882017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dinkelspiel HE, Wright JD, Lewin SN and
Herzog TJ: Contemporary clinical management of endometrial cancer.
Obstet Gynecol Int. 2013:5838912013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Colombo N, Preti E, Landoni F, Carinelli
S, Colombo A, Marini C and Sessa C: ESMO Guidelines Working Group:
Endometrial cancer: ESMO clinical practice guidelines for
diagnosis, treatment and follow-up. Ann Oncol. 24 Suppl
6:vi33–vi38. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Davidson BA, Foote J, Clark LH, Broadwater
G, Ehrisman J, Gehrig P, Graybill W, Secord Alvarez A and
Havrilesky LJ: Tumor grade and chemotherapy response in
endometrioid endometrial cancer. Gynecol Oncol Rep. 17:3–6. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
West KA, Castillo SS and Dennis PA:
Activation of the PI3K/Akt pathway and chemotherapeutic resistance.
Drug Resist Updat. 5:234–248. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mohammad RM, Muqbil I, Lowe L, Yedjou C,
Hsu HY, Lin LT, Siegelin MD, Fimognari C, Kumar NB, Dou QP, et al:
Broad targeting of resistance to apoptosis in cancer. Semin Cancer
Biol. 35 Suppl:S78–S103. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Johnston SR: Enhancing endocrine therapy
for hormone receptor-positive advanced breast cancer: Cotargeting
signaling pathways. J Natl Cancer Inst. 107:pii: djv212. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Catalanotto C, Cogoni C and Zardo G:
MicroRNA in control of gene expression: An overview of nuclear
functions. Int J Mol Sci. 17:pii: E1712. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Macfarlane LA and Murphy PR: MicroRNA:
Biogenesis, function and role in cancer. Curr Genomics. 11:537–561.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pillai RS: MicroRNA function: Multiple
mechanisms for a tiny RNA? RNA. 11:1753–1761. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hiroki E, Suzuki F, Akahira J, Nagase S,
Ito K, Sugawara J, Miki Y, Suzuki T, Sasano H and Yaegashi N:
MicroRNA-34b functions as a potential tumor suppressor in
endometrial serous adenocarcinoma. Int J Cancer. 131:E395–E404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Z, Wang W, Huang K, Wang Y, Li J and
Yang X: MicroRNA-34a inhibits cells proliferation and invasion by
downregulating Notch1 in endometrial cancer. Oncotarget.
8:111258–111270. 2017.PubMed/NCBI
|
|
16
|
Torres A, Torres K, Pesci A, Ceccaroni M,
Paszkowski T, Cassandrini P, Zamboni G and Maciejewski R:
Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma
coexists with increased expression of mTOR kinase in endometrioid
endometrial carcinoma. BMC Cancer. 12:3692012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Riss TL, Moravec RA, Niles AL, et al: Cell
viability assaysSittampalam GS, Coussens NP, Brimacombe K, et al:
Assay Guidance Manual. Bethesda (MD): 2004, View Article : Google Scholar
|
|
19
|
Yanokura M, Banno K, Iida M, Irie H, Umene
K, Masuda K, Kobayashi Y, Tominaga E and Aoki D: MicroRNAS in
endometrial cancer: Recent advances and potential clinical
applications. EXCLI J. 14:190–198. 2015.PubMed/NCBI
|
|
20
|
Lin J, Huang S, Wu S, Ding J, Zhao Y,
Liang L, Tian Q, Zha R, Zhan R and He X: MicroRNA-423 promotes cell
growth and regulates G(1)/S transition by targeting p21Cip1/Waf1 in
hepatocellular carcinoma. Carcinogenesis. 32:1641–1647. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao H, Gao A, Zhang Z, Tian R, Luo A, Li
M, Zhao D, Fu L, Fu L, Dong JT and Zhu Z: Genetic analysis and
preliminary function study of miR-423 in breast cancer. Tumour
Biol. 36:4763–4771. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Volinia S, Galasso M, Sana ME, Wise TF,
Palatini J, Huebner K and Croce CM: Breast cancer signatures for
invasiveness and prognosis defined by deep sequencing of microRNA.
Proc Natl Acad Sci USA. 109:3024–3029. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Moxley KM and McMeekin DS: Endometrial
carcinoma: A review of chemotherapy, drug resistance, and the
search for new agents. Oncologist. 15:1026–1033. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Abdullah LN and Chow EK: Mechanisms of
chemoresistance in cancer stem cells. Clin Transl Med. 2:32013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zheng HC: The molecular mechanisms of
chemoresistance in cancers. Oncotarget. 8:59950–59964.
2017.PubMed/NCBI
|
|
27
|
Meng F, Henson R, Lang M, Wehbe H,
Maheshwari S, Mendell JT, Jiang J, Schmittgen TD and Patel T:
Involvement of human micro-RNA in growth and response to
chemotherapy in human cholangiocarcinoma cell lines.
Gastroenterology. 130:2113–2129. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang H, Kong W, He L, Zhao JJ, O'Donnell
JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV and Cheng JQ:
MicroRNA expression profiling in human ovarian cancer: miR-214
induces cell survival and cisplatin resistance by targeting PTEN.
Cancer Res. 68:425–433. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kong W, He L, Coppola M, Esposito NN,
Coppola D and Cheng JQ: MicroRNA-155 regulates cell survival,
growth, and chemosensitivity by targeting FOXO3a in breast cancer.
J Biol Chem. 291:228552016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yu Z, Xu Z, Disante G, Wright J, Wang M,
Li Y, Zhao Q, Ren T, Ju X, Gutman E, et al: miR-17/20 sensitization
of breast cancer cells to chemotherapy-induced apoptosis requires
Akt1. Oncotarget. 5:1083–1090. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li L and Li W: Epithelial-mesenchymal
transition in human cancer: Comprehensive reprogramming of
metabolism, epigenetics, and differentiation. Pharmacol Ther.
150:33–46. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gregory PA, Bert AG, Paterson EL, Barry
SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ:
The miR-200 family and miR-205 regulate epithelial to mesenchymal
transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xie Y, Naizabekov S, Chen Z and Tokay T:
Power of PTEN/AKT: Molecular switch between tumor suppressors and
oncogenes. Oncol Lett. 12:375–378. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu W, Yang Z, Zhou SF and Lu N:
Posttranslational regulation of phosphatase and tensin homolog
(PTEN) and its functional impact on cancer behaviors. Drug Des
Devel Ther. 8:1745–1751. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Djordjevic B, Hennessy BT, Li J, Barkoh
BA, Luthra R, Mills GB and Broaddus RR: Clinical assessment of PTEN
loss in endometrial carcinoma: Immunohistochemistry outperforms
gene sequencing. Mod Pathol. 25:699–708. 2012. View Article : Google Scholar : PubMed/NCBI
|
